California State Teachers Retirement System Sells 2,182 Shares of Lantheus Holdings, Inc. $LNTH

California State Teachers Retirement System trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,025 shares of the medical equipment provider's stock after selling 2,182 shares during the quarter. California State Teachers Retirement System owned approximately 0.12% of Lantheus worth $8,434,214 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Jupiter Topco LLC acquired a new stake in Lantheus in the 2nd quarter worth about $575,628,000. ABS Investment Management LLC purchased a new stake in shares of Lantheus during the 2nd quarter worth about $232,974,000. Reinhart Partners LLC. boosted its stake in Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider's stock valued at $177,437,000 after acquiring an additional 34,501 shares during the last quarter. Carmignac Gestion boosted its stake in Lantheus by 18.4% during the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider's stock valued at $100,729,000 after purchasing an additional 206,000 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider's stock valued at $79,320,000 after acquiring an additional 582,661 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Up 0.4%

LNTH stock traded up $0.36 during midday trading on Tuesday, reaching $100.69. 638,208 shares of the company's stock traded hands, compared to its average volume of 1,095,063. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86. The business has a 50-day moving average price of $102.13 and a two-hundred day moving average price of $94.07. The company has a market capitalization of $6.57 billion, a P/E ratio of 24.32 and a beta of -0.03.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to analysts' expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.Lantheus's revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.57 earnings per share. Equities research analysts forecast that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research reports. Truist Financial lowered shares of Lantheus from a "buy" rating to a "hold" rating and lowered their price target for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Leerink Partners set a $102.50 target price on shares of Lantheus in a research note on Monday, August 3rd. William Blair set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. B. Riley Financial lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Monday, August 17th. Finally, TD Cowen downgraded Lantheus from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $110.00 to $102.50 in a research note on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc NASDAQ: LNTH is a healthcare company that develops, manufactures and commercializes diagnostic imaging agents and radiopharmaceuticals. Its products are designed to help physicians detect, characterize and monitor disease, with applications in cardiology, oncology and other areas of medicine.

The company's principal products include DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound images, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and assess prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.